This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

The present invention relates to a method for producing a morpholino nucleic acid oligomer (each symbol is as defined in the description), the method including a step for treating a compound of formula (II) using a solution that contains an acid and a scavenger in an elongation reaction of a morpholino nucleic acid oligomer represented by the following formula and removing R.sup.1 from the compound of formula (II) to produce a compound of formula (III).

##STR00001##

The present invention relates to a method for producing a morpholino nucleic acid oligomer (each symbol is as defined in the description), the method including a step for treating a compound of formula (II) using a solution that contains an acid and a scavenger in an elongation reaction of a morpholino nucleic acid oligomer represented by the following formula and removing R.sup.1 from the compound of formula (II) to produce a compound of formula (III).

##STR00001##

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

An organic light-emitting device including a first electrode; a second electrode facing the first electrode; and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer, wherein the organic layer includes a compound represented by Formula 1:

##STR00001##

When the compound represented by Formula 1 is used as electron-transporting material, an organic light-emitting device including this compound may show significantly improved efficiency, driving voltage, high luminance, and long lifespan characteristics.

The present invention provides phosphoryl choline derivatives of general formula (I), which are suitable to be immobilized on a solid support to provide a separation material of general formula (II), which bind with both high affinity and high specificity to a protein, more specifically to C-reactive protein and anti-phosphoryl choline antibodies. Said separation materials are particularly useful in the extracorporeal removal of C-reactive protein and anti-phosphoryl choline antibodies from a biological fluid of a patient for prophylaxis and/or treatment of immune dysfunctions and cardiovascular diseases. Also provided is a column that comprises the separation material of general formula (II), as well as a device containing the column. Formula (I), wherein variable X is selected from: SH, NHR.sup.3, CCH, CHCH.sub.2, N.sub.3and CHO; the other variables are as defined in the claims: Formula (II), wherein variable A represents a solid support. A as well as the other variables are defined in detail in the claims.

##STR00001##